Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) has been given an average broker rating score of 1.25 (Strong Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy recommendation and three have issued a strong buy recommendation on the company. Osmotica Pharmaceuticals’ rating score has improved by 6% in the last 90 days as a result of a number of analysts’ upgrades and downgrades.
Brokerages have set a one year consensus price target of $13.75 for the company and are predicting that the company will post ($0.04) earnings per share for the current quarter, according to Zacks. Zacks has also given Osmotica Pharmaceuticals an industry rank of 66 out of 256 based on the ratings given to related companies.
OSMT has been the topic of several recent analyst reports. Barclays initiated coverage on shares of Osmotica Pharmaceuticals in a report on Tuesday, June 11th. They issued an “overweight” rating and a $11.00 target price on the stock. Wells Fargo & Co set a $14.00 target price on shares of Osmotica Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, March 28th. Finally, Zacks Investment Research lowered shares of Osmotica Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, April 25th.
A number of hedge funds have recently added to or reduced their stakes in OSMT. SG Americas Securities LLC acquired a new position in shares of Osmotica Pharmaceuticals during the first quarter valued at about $45,000. American International Group Inc. acquired a new position in shares of Osmotica Pharmaceuticals during the fourth quarter valued at about $50,000. Deutsche Bank AG acquired a new position in shares of Osmotica Pharmaceuticals during the fourth quarter valued at about $111,000. Northern Trust Corp acquired a new position in shares of Osmotica Pharmaceuticals during the fourth quarter valued at about $615,000. Finally, Geode Capital Management LLC acquired a new position in shares of Osmotica Pharmaceuticals during the fourth quarter valued at about $668,000. Institutional investors and hedge funds own 11.64% of the company’s stock.
Shares of Osmotica Pharmaceuticals stock traded up $0.02 during trading on Monday, hitting $3.31. The company’s stock had a trading volume of 95,239 shares, compared to its average volume of 114,049. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.41 and a current ratio of 1.70. Osmotica Pharmaceuticals has a 52 week low of $2.20 and a 52 week high of $9.90. The stock has a market capitalization of $169.50 million and a PE ratio of -6.49. The firm’s 50-day moving average is $2.81.
Osmotica Pharmaceuticals (NASDAQ:OSMT) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.08). The company had revenue of $57.13 million for the quarter, compared to the consensus estimate of $53.58 million. Analysts predict that Osmotica Pharmaceuticals will post -0.25 EPS for the current fiscal year.
Osmotica Pharmaceuticals Company Profile
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.
Featured Story: How is diluted EPS different from basic EPS?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.